Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting
Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…Abstract Number: 3148 • 2016 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the…Abstract Number: 1111 • 2016 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Receptor Tyrosine Kinases Mediated Activity and Cell Invasiness in Fibroblast-like Synoviocytes
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is a new arthritis severity gene recently identified in the Pristane and Collagen-induced arthritis (PIA, CIA) quantitative trait locus Cia25/Pia42…Abstract Number: 1435 • 2016 ACR/ARHP Annual Meeting
KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Background/Purpose: Fibroblast-like synoviocytes (FLS) develop a high degree of invasiveness during rheumatoid arthritis (RA), leading to joint degradation. There are currently no therapeutics that specifically…Abstract Number: 1436 • 2016 ACR/ARHP Annual Meeting
TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis
Background/Purpose: The family of Janus kinases (JAKs) plays important roles in signaling pathway mediated by various cytokine receptors. An aberrant activation of JAK-STAT signaling…Abstract Number: 1618 • 2015 ACR/ARHP Annual Meeting
The Protective Effect of HLA-DRB1*13 Alleles during Specific Phases in the Development of ACPA-Positive RA
Background/Purpose: HLA-DRB1*13 alleles are associated with protection from anti-citrullinated protein antibody (ACPA-)positive rheumatoid arthritis (RA). It is however unknown at which phase of disease development…Abstract Number: 2732 • 2015 ACR/ARHP Annual Meeting
The Effect of Adrenocorticotropin Gel (HP Acthar Gel) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective
Background/Purpose: Although adrenocorticotropin (ACTH) gel was approved by the FDA for the treatment of RA in 1952, data on its clinical and structural benefits for…Abstract Number: 1622 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Analysis and Whole Genome Sequencing Identify Variants Associated with Radiographic Severity of Rheumatoid Arthritis in African Americans
Background/Purpose: Joint damage manifested by bony erosions and joint space narrowing is a major contributor to the morbidity and mortality of RA. Reports in Caucasians…Abstract Number: 3098 • 2015 ACR/ARHP Annual Meeting
Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease at 12 Months: Results from the Pathobiology of Early Arthritis Cohort
Background/Purpose: The inflammatory cell infiltrate in RA synovium has been recognised to organise into lymphocytic aggregates (Ags) with data to suggest that these structures are…Abstract Number: 1646 • 2015 ACR/ARHP Annual Meeting
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting? the ACT-Solo Study: An Analysis of Efficacy and Safety at 12 Months
Background/Purpose: Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…Abstract Number: 3136 • 2015 ACR/ARHP Annual Meeting
Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Background/Purpose: More than 90% of patients with Systemic Sclerosis (SSc) have gastroinstestinal (GI) involvement, commonly dysmotility causing complications such as gastroesophageal reflux and constipation. Treatment…Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting
The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis
Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting
Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages
Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…Abstract Number: 1656 • 2015 ACR/ARHP Annual Meeting
Repeated CD4+ T-Cell Depletion in Patients with Rheumatoid Arthritis over Multiple Cycles of Rituximab Treatment
Background/Purpose: CD4+ T-cell depletion after a first cycle of rituximab (RTX) in patients with rheumatoid arthritis (RA) was previously reported by our group (Mélet J…Abstract Number: 3198 • 2015 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Background/Purpose: ACT-iON was a global, multicenter, observational, 52-wk, clinical practice study of the effectiveness of tocilizumab (TCZ) vs anti–tumor necrosis factor (aTNF) agents prescribed as…
- « Previous Page
- 1
- …
- 173
- 174
- 175
- 176
- 177
- …
- 188
- Next Page »